Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos ...Middle East

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Hence then, the article about q2fy23 preview modest revenue growth ebitda decline seen in pharma cos was published today ( Wednesday 26/10/2022 - 11:33 AM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos )

Also on site :

• Trump’s Trade Negotiator Says Response to Court Loss Would Be Immediate
• Wahed launches pioneering UCITS ETFs with additional values based screen considering human rights and injustice
• OpenLedger Partners With Theoriq to Bring Verifiable AI Agents Into Live DeFi Markets